Milae Bioresources Co., Ltd. (KOSDAQ:218150)
South Korea · Delayed Price · Currency is KRW 2,085.00
-25.00 (-1.18%)
At close: Jun 5, 2026
Milae Bioresources Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 69,889 | 67,555 | 62,453 | 60,016 | 75,635 | 66,668 | |
Revenue Growth (YoY) | 11.45% | 8.17% | 4.06% | -20.65% | 13.45% | 40.36% |
Cost of Revenue | 59,631 | 57,512 | 54,554 | 51,911 | 66,210 | 58,308 |
Gross Profit | 10,258 | 10,043 | 7,900 | 8,105 | 9,425 | 8,361 |
Selling, General & Admin | 6,418 | 6,682 | 6,574 | 6,943 | 6,757 | 5,530 |
Research & Development | 821.17 | 576.7 | 545.24 | 534.89 | 521.61 | 461.83 |
Amortization of Goodwill & Intangibles | 434.02 | 427.38 | 114.02 | 153.7 | 183.97 | 170.86 |
Other Operating Expenses | 178.46 | 75.66 | 43.34 | 40.55 | 56.06 | 14.76 |
Operating Expenses | 11,422 | 11,490 | 7,716 | 8,084 | 7,842 | 6,506 |
Operating Income | -1,164 | -1,448 | 183.74 | 20.19 | 1,583 | 1,855 |
Interest Expense | -410.48 | -471.52 | -439.5 | -399.63 | -685.42 | -778.2 |
Interest & Investment Income | 332.03 | 348.45 | 731.35 | 1,008 | 366.78 | 116.75 |
Earnings From Equity Investments | - | 456.28 | - | - | - | - |
Currency Exchange Gain (Loss) | 167.38 | 64.43 | -9.52 | -13.87 | -4.61 | 2.25 |
Other Non Operating Income (Expenses) | 34.17 | 16.78 | -114.25 | -12.44 | -63.6 | -16.15 |
EBT Excluding Unusual Items | -1,041 | -1,033 | 351.81 | 601.8 | 1,196 | 1,180 |
Gain (Loss) on Sale of Investments | - | - | - | 1.6 | -303.33 | -41.2 |
Gain (Loss) on Sale of Assets | -23.07 | 27.96 | 5.88 | 6.94 | 12.8 | 5.73 |
Asset Writedown | -1,616 | -1,616 | -875.01 | -356.45 | - | - |
Other Unusual Items | 5.5 | 5.5 | - | 139.06 | - | - |
Pretax Income | -2,675 | -2,616 | -517.31 | 392.95 | 905.4 | 1,144 |
Income Tax Expense | 347.24 | 373.38 | -97.58 | 33.74 | 27.25 | 65.28 |
Earnings From Continuing Operations | -3,023 | -2,990 | -419.73 | 359.21 | 878.15 | 1,079 |
Minority Interest in Earnings | -266.82 | -269.86 | -13.77 | 82.14 | 84.62 | 63.79 |
Net Income | -3,289 | -3,259 | -433.5 | 441.35 | 962.77 | 1,143 |
Net Income to Common | -3,289 | -3,259 | -433.5 | 441.35 | 962.77 | 1,143 |
Net Income Growth | - | - | - | -54.16% | -15.75% | 20.05% |
Shares Outstanding (Basic) | 19 | 19 | 20 | 19 | 19 | 18 |
Shares Outstanding (Diluted) | 19 | 19 | 20 | 19 | 19 | 18 |
Shares Change (YoY) | -1.48% | -1.06% | 2.42% | 2.90% | 5.51% | -0.06% |
EPS (Basic) | -169.59 | -167.19 | -22.00 | 22.94 | 51.50 | 64.49 |
EPS (Diluted) | -169.59 | -167.19 | -22.00 | 22.94 | 51.00 | 64.00 |
EPS Growth | - | - | - | -55.02% | -20.31% | 19.22% |
Free Cash Flow | 2,155 | 4,000 | -1,069 | 2,603 | 706.43 | 2,452 |
Free Cash Flow Per Share | 111.09 | 205.17 | -54.24 | 135.29 | 37.78 | 138.38 |
Gross Margin | 14.68% | 14.87% | 12.65% | 13.50% | 12.46% | 12.54% |
Operating Margin | -1.67% | -2.14% | 0.29% | 0.03% | 2.09% | 2.78% |
Profit Margin | -4.71% | -4.83% | -0.69% | 0.73% | 1.27% | 1.71% |
Free Cash Flow Margin | 3.08% | 5.92% | -1.71% | 4.34% | 0.93% | 3.68% |
EBITDA | 1,060 | 790.08 | 1,357 | 1,076 | 2,612 | 2,776 |
EBITDA Margin | 1.52% | 1.17% | 2.17% | 1.79% | 3.45% | 4.16% |
D&A For EBITDA | 2,224 | 2,238 | 1,173 | 1,056 | 1,029 | 920.77 |
EBIT | -1,164 | -1,448 | 183.74 | 20.19 | 1,583 | 1,855 |
EBIT Margin | -1.67% | -2.14% | 0.29% | 0.03% | 2.09% | 2.78% |
Effective Tax Rate | - | - | - | 8.59% | 3.01% | 5.71% |
Advertising Expenses | - | 491.73 | 331.9 | 515.17 | 418.44 | 106.4 |